Playwright is one of the most widely adopted browser automation frameworks available today. Engineering teams use it for end-to-end web testing, cross-browser coverage, and increasingly, AI-based test generation. But teams that rely on Playwright alone often find themselves maintaining a test platform rather than releasing higher quality business software.
This whitepaper examines why QA and engineering teams that start with Playwright eventually migrate to XPeer.AI and what drives that decision.
Playwright automates browser actions. It does not help eliminate bugs. Test suites built on Playwright require specialist automation engineers to create, maintain, and stabilize scripts. As products evolve, UI changes break tests. Infrastructure and maintenance costs accumulate. Teams who should be building features spend time maintaining fragile test scripts and flaky tests instead.
The result is a common pattern: teams claim 80% automation coverage on paper, but in practice, suites are outdated, unreliable, or too slow to maintain. Quality becomes a bottleneck rather than an enabler.
Inside This Whitepaper
- Execution reliability vs long-term maintenance cost at scale.
- How teams handle feature velocity with limited QA bandwidth.
- The operational gap between test pass rates and true release confidence.
- Decision criteria for hybrid and phased adoption patterns.
What Makes XPeer.ai Different
- Tests are robust, the recorded tests keep updating themselves as your platform grows to ensure minimal manual maintenance efforts are required.
- UI and API layers are validated together in a single user journey, eliminating the blind spots created by separate testing stacks.
- Bug elimination is the goal, not bug detection.
- Developers, QAs, product managers, business users can all use the platform and review tests without any specialised framework knowledge.
- Developers can run QA Peer locally before code reaches QA environments, catching defects at the lowest cost point.
Who should read this whitepaper
- Spending more time maintaining test scripts than building features
- Seeing high test pass rates but continued production bugs
- Struggling to keep automation aligned with a fast-moving product
- Looking to reduce dependency on fragile modern-test automation tools like Playwright
- Evaluating a transition from Playwright to an AI-native QA approach
Download the Full Whitepaper
Access detailed benchmark scenarios, capability mapping, and a practical transition strategy used by high-growth product teams.
Statistics cited are drawn from published research including Johns Hopkins Patient Safety data, CMS regulatory guidance, and XPeer.ai customer outcomes. Individual results may vary based on organization size, technology environment, and implementation scope.